What does this research mean for the field?

Pre-treatment tumor CD19 expression levels are a clinically meaningful determinant of progression-free survival following CD19 CAR T-cell therapy in large B-cell lymphoma, with lower expression correlating with significantly worse outcomes. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To determine whether quantitative levels of tumor CD19 expression affect clinical outcomes in patients receiving CD19-directed CAR T-cell therapy for large B-cell lymphoma.

September 2, 2026Blood Cancer Discovery

Tumor CD19 Expression Determines Distinct Clinical Outcomes After CD19 CAR T-Cell Therapy in Large B-Cell Lymphoma

View Full Paper

Ask AI

Bookmark

Authors

MCMagdalena CoronaMemorial Sloan Kettering Cancer Center AGAaron GillmorMemorial Sloan Kettering Cancer Center KAKimon V. ArgyropoulosMemorial Sloan Kettering Cancer Center

Discussion

Member takes

Implication

Cohort study reveals higher tumor CD19 levels improve progression-free survival in large B-cell lymphoma, indicating quantitative assessment enhances risk stratification.

Key Points

To determine whether quantitative levels of tumor CD19 expression affect clinical outcomes in patients receiving CD19-directed CAR T-cell therapy for large B-cell lymphoma.
Conducted centralized quantitative tumor CD19 assessment using flow cytometry, immunohistochemistry, and RNA-sequencing in a primary cohort (n=301) receiving axicabtagene ciloleucel or lisocabtagene maraleucel.
Performed transcriptomic profiling and validated associations with inflammatory pathways in an independent external cohort (n=1,017), alongside genomic profiling of CD19 alterations.
Pre-treatment CD19 levels by flow cytometry correlated significantly with 1-year progression-free survival rates: 16% for CD19low, 53% for CD19intermediate, and 64% for CD19high (p=0.005).
The frequency of CD19low tumors increased from 17% prior to therapy to 35% following disease relapse.
Genetic loss of the CD19 locus occurred in 8% of pre-treatment and 11% of post-treatment tumors (p=0.82), with no CD19 coding mutations detected.

Cite This Study

Corona et al. (2026) studied this question.

synapsesocial.com/papers/6a97e2b1c562ede874ec6e5d https://doi.org/10.1158/2643-3230.bcd-25-0501

View Full Paper

Ask AI

Bookmark

September 2, 2026Blood Cancer Discovery

Tumor CD19 Expression Determines Distinct Clinical Outcomes After CD19 CAR T-Cell Therapy in Large B-Cell Lymphoma

View Full Paper

Ask AI

Bookmark

Authors

MCMagdalena CoronaMemorial Sloan Kettering Cancer Center AGAaron GillmorMemorial Sloan Kettering Cancer Center KAKimon V. ArgyropoulosMemorial Sloan Kettering Cancer Center

Discussion

Member takes

Implication

Cohort study reveals higher tumor CD19 levels improve progression-free survival in large B-cell lymphoma, indicating quantitative assessment enhances risk stratification.

Key Points

To determine whether quantitative levels of tumor CD19 expression affect clinical outcomes in patients receiving CD19-directed CAR T-cell therapy for large B-cell lymphoma.
Conducted centralized quantitative tumor CD19 assessment using flow cytometry, immunohistochemistry, and RNA-sequencing in a primary cohort (n=301) receiving axicabtagene ciloleucel or lisocabtagene maraleucel.
Performed transcriptomic profiling and validated associations with inflammatory pathways in an independent external cohort (n=1,017), alongside genomic profiling of CD19 alterations.
Pre-treatment CD19 levels by flow cytometry correlated significantly with 1-year progression-free survival rates: 16% for CD19low, 53% for CD19intermediate, and 64% for CD19high (p=0.005).
The frequency of CD19low tumors increased from 17% prior to therapy to 35% following disease relapse.
Genetic loss of the CD19 locus occurred in 8% of pre-treatment and 11% of post-treatment tumors (p=0.82), with no CD19 coding mutations detected.

Cite This Study

Corona et al. (2026) studied this question.

synapsesocial.com/papers/6a97e2b1c562ede874ec6e5d https://doi.org/10.1158/2643-3230.bcd-25-0501

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark